Top ASX Penny Stocks To Watch In June 2025

The Australian market is bracing for a slight downturn, with ASX 200 futures indicating a -0.2% slide amid geopolitical tensions involving the U.S. and Iran, and mixed economic signals from Europe and Russia. In such uncertain times, investors often look toward penny stocks—an investment area that remains relevant despite its somewhat outdated terminology—for potential growth opportunities in smaller or newer companies. These stocks can offer a mix of affordability and potential when backed by strong financial health, making them intriguing options for those seeking to explore under-the-radar opportunities in the market.
Name
Share Price
Market Cap
Financial Health Rating
EZZ Life Science Holdings (ASX:EZZ)
A$2.31
A$108.97M
★★★★★★
GTN (ASX:GTN)
A$0.615
A$117.37M
★★★★★★
IVE Group (ASX:IGL)
A$2.72
A$419.37M
★★★★★☆
West African Resources (ASX:WAF)
A$2.19
A$2.5B
★★★★★★
Southern Cross Electrical Engineering (ASX:SXE)
A$1.71
A$452.14M
★★★★★★
Tasmea (ASX:TEA)
A$3.19
A$751.63M
★★★★★☆
Regal Partners (ASX:RPL)
A$2.11
A$709.31M
★★★★★★
Lindsay Australia (ASX:LAU)
A$0.69
A$218.85M
★★★★☆☆
Bisalloy Steel Group (ASX:BIS)
A$3.26
A$154.69M
★★★★★★
CTI Logistics (ASX:CLX)
A$1.735
A$139.74M
★★★★☆☆
Click here to see the full list of 1,007 stocks from our ASX Penny Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Brazilian Rare Earths Limited is engaged in the exploration of rare earth elements and other critical minerals in Brazil, with a market cap of A$571.20 million.
Operations: Currently, there are no reported revenue segments for Brazilian Rare Earths Limited.
Market Cap: A$571.2M
Brazilian Rare Earths Limited, with a market cap of A$571.20 million, remains pre-revenue and unprofitable but has shown significant progress in its exploration activities. Recent milestones include the successful production of mixed-rare earth carbonate and uranium peroxide from the Monte Alto Project, highlighting potential for high-value product streams like NdPr oxide and uranium yellowcake. The Sulista Project has confirmed ultra-high-grade deposits, expanding exploration potential. Despite being debt-free with no long-term liabilities, BRE's management team is relatively inexperienced. However, it maintains a stable cash runway exceeding one year to support ongoing development efforts.
Get an in-depth perspective on Brazilian Rare Earths' performance by reading our balance sheet health report here.
Assess Brazilian Rare Earths' future earnings estimates with our detailed growth reports.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Rand Mining Limited is involved in the exploration, development, and production of mineral properties in Australia with a market cap of A$120.01 million.
Operations: The company generates revenue from its Metals & Mining segment, specifically in Gold & Other Precious Metals, amounting to A$41.11 million.
Market Cap: A$120.01M
Rand Mining Limited, with a market cap of A$120.01 million, benefits from stable weekly volatility and a seasoned management team averaging 22.4 years of tenure. The company has shown consistent earnings growth over the past five years at 19.5% annually, outperforming the industry average last year with a 16.8% increase in earnings despite a slight deceleration from its historical rate. Rand Mining's financial health is robust, as it remains debt-free with short-term assets covering both short- and long-term liabilities comfortably. However, its return on equity remains low at 8.8%, and net profit margins have slightly decreased to 21.6%.
Navigate through the intricacies of Rand Mining with our comprehensive balance sheet health report here.
Gain insights into Rand Mining's historical outcomes by reviewing our past performance report.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Simonds Group Limited, along with its subsidiaries, is involved in the design, construction, and sale of residential dwellings in Australia and has a market cap of A$59.38 million.
Operations: The company's revenue is primarily generated from its Residential Construction segment, amounting to A$644.56 million.
Market Cap: A$59.38M
Simonds Group Limited, with a market cap of A$59.38 million, has recently become profitable, though its earnings growth rate is difficult to compare due to past losses. The company maintains strong financial health with short-term assets exceeding both short- and long-term liabilities and more cash than total debt. However, its interest coverage ratio remains below ideal levels at 2.9x EBIT. Recent executive changes include the appointment of Rhett Simonds as CEO and strategic board adjustments aimed at enhancing financial oversight. Despite trading significantly below estimated fair value, the company's share price has been highly volatile recently.
Jump into the full analysis health report here for a deeper understanding of Simonds Group.
Examine Simonds Group's past performance report to understand how it has performed in prior years.
Jump into our full catalog of 1,007 ASX Penny Stocks here.
Looking For Alternative Opportunities? Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ASX:BRE ASX:RND and ASX:SIO.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

14 minutes ago

• Yahoo

Investors in IHH Healthcare Berhad (KLSE:IHH) have seen notable returns of 38% over the past five years

When we invest, we're generally looking for stocks that outperform the market average. And in our experience, buying the right stocks can give your wealth a significant boost. For example, the IHH Healthcare Berhad (KLSE:IHH) share price is up 28% in the last 5 years, clearly besting the market return of around 6.4% (ignoring dividends). On the other hand, the more recent gains haven't been so impressive, with shareholders gaining just 12%, including dividends. So let's assess the underlying fundamentals over the last 5 years and see if they've moved in lock-step with shareholder returns. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. Over half a decade, IHH Healthcare Berhad managed to grow its earnings per share at 114% a year. The EPS growth is more impressive than the yearly share price gain of 5% over the same period. So it seems the market isn't so enthusiastic about the stock these days. You can see below how EPS has changed over time (discover the exact values by clicking on the image). Dive deeper into IHH Healthcare Berhad's key metrics by checking this interactive graph of IHH Healthcare Berhad's earnings, revenue and cash flow. As well as measuring the share price return, investors should also consider the total shareholder return (TSR). The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. We note that for IHH Healthcare Berhad the TSR over the last 5 years was 38%, which is better than the share price return mentioned above. This is largely a result of its dividend payments! It's good to see that IHH Healthcare Berhad has rewarded shareholders with a total shareholder return of 12% in the last twelve months. That's including the dividend. Since the one-year TSR is better than the five-year TSR (the latter coming in at 7% per year), it would seem that the stock's performance has improved in recent times. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. Before forming an opinion on IHH Healthcare Berhad you might want to consider these 3 valuation metrics. If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Malaysian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Associated Press

22 minutes ago

• Associated Press

Spetz Announces Closing of Third and Final Tranche of Private Placement for an Aggregate Total of $8,502,761.50 Million

TORONTO, ON / ACCESS Newswire / June 20, 2025 / SPETZ INC. (the 'Company' or 'Spetz') (CSE:SPTZ)(OTC PINK:DBKSF) is pleased to announce that it has held earlier today the closing of the third and final tranche (the 'Third Tranche') of its previously announced non-brokered private placement (the 'Private Placement') at which it issued 796,906 units (the 'Units') at a price of $0.50 per Unit, for gross proceeds of $398,453. Each of the Units is comprised of one common share and one-half of a common share purchase warrant (the 'Warrants') of Spetz. Each whole Warrant entitles its holder to acquire one additional common share of Spetz at a price of $0.75 for a period of 24 months from the closing date. As previously announced, the Company issued 16,208,617 Units for gross proceeds of $8,104,308.50 on May 28, 2025 and June 18, 2025, respectively. In aggregate, the Company issued under the Private Placement 17,005,523 Units for aggregate gross proceeds of $8,502,761.50. The net proceeds from the Private Placement will be used for general working capital purposes, validator expansion, and growth initiatives within the blockchain infrastructure sector. In connection with the Third Tranche, the Company paid cash commissions to two (2) securities dealers in an aggregate amount of $6 507.18. In addition, the Company granted non-transferable finders' warrants (the 'Finder's Warrants') to two (2) securities dealers entitling them to acquire up to an aggregate of 10,014 additional common shares of Spetz at a price of $0.75 per share for a period of 24 months from the closing date. All of the foregoing securities issued under the Third Tranche are subject to a hold period of four months and day expiring on October 21, 2025. About Spetz Inc. (dba SonicStrategy) Spetz Inc. (dba SonicStrategy) (CSE:SPTZ)(OTC PINK:DBKSF) is the parent company of SonicStrategy Inc., a public-market gateway to the Sonic blockchain ecosystem. Spetz provides investors with compliant exposure to staking infrastructure and DeFi strategies across the Sonic network. Company Contacts: Investor Relations Email: [email protected] Mitchell Demeter Email: [email protected] Phone: 345-936-9555 NEITHER THE CANADIAN SECURITIES EXCHANGE, NOR THEIR REGULATION SERVICES PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Cautionary Note Regarding Forward-looking Statements Certain information herein constitutes 'forward-looking information' under Canadian securities laws, reflecting management's expectations regarding objectives, plans, strategies, future growth, results of operations, and business prospects of the Company. Words such as 'may', 'plans,' 'expects,' 'intends,' 'anticipates,' 'believes,' and similar expressions identify forward-looking statements, which are qualified by the inherent risks and uncertainties surrounding future expectations. Forward-looking statements are based on a number of estimates and assumptions that, while considered reasonable by management, are subject to business, economic, and competitive uncertainties and contingencies. The Company cautions readers not to place undue reliance on these statements, as forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from projected outcomes. Factors influencing these outcomes include economic conditions, regulatory developments, competition, capital availability, and business execution risks. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. The forward-looking information contained in this press release represents Spetz's expectations as of the date of this release and is subject to change. Spetz does not undertake any obligation to update forward-looking statements, except as required by law. This press release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction. None of the securities issued in the Private Placement will be registered under the United States Securities Act of 1933, as amended (the '1933 Act'), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. We seek Safe Harbor. SOURCE: Spetz Inc press release

Yahoo

28 minutes ago

• Yahoo

PPL Corp. price target lowered to $37 from $38 at Morgan Stanley

Morgan Stanley lowered the firm's price target on PPL Corp. (PPL) to $37 from $38 and keeps an Overweight rating on the shares. The firm is updating its price targets for stocks in the Regulated & Diversified Utilities / IPPs North America sector, noting utilities underperformed the S&P in May, the analyst tells investors. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on PPL: Disclaimer & DisclosureReport an Issue Chesapeake Utilities names Abhijit Bhatwadekar as Chief Information Officer PPL Shareholders Elect Directors, Approve Executive Compensation PPL Subsidiaries Seek Revenue Increases for System Upgrades PPL Reaffirms 2025 Earnings Guidance in May 2025 PPL Corp. price target raised to $40 from $38 at Guggenheim Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data